A1ZN34:BVMF
AstraZeneca
139,90 BRL
0,00%
(0,00) 1 д.
16.10, 17:06:00 ч. Гринуич-3 · BRL
search
Всички символи
| Символ | Цена | Промяна | % промяна |
|---|
insights_autoГенерира се водещата статистика за A1ZN34…
Отваряне
143,33 BRL
Висока
143,33 BRL
Ниска
138,81 BRL
Пазарна кап.
259,42 млрд.
Ср. обем
892,00
Обем
1,25 хил.
Най-висока цена за 52 седм.
190,40 BRL
Най-ниска цена за 52 седм.
129,06 BRL
Акции в обращение
1,55 млрд.
Брой служители
96 хил.
Отваряне
143,33 BRL
Висока
143,33 BRL
Ниска
138,81 BRL
Пазарна кап.
259,42 млрд.
Ср. обем
892,00
Обем
1,25 хил.
Най-висока цена за 52 седм.
190,40 BRL
Най-ниска цена за 52 седм.
129,06 BRL
Акции в обращение
1,55 млрд.
Брой служители
96 хил.
Новинарски материали
От източници в мрежата и новинарски партньори
Yahoo Finance
·
преди 23 часа
Summit Therapeutics (SMMT) Stock Fair Value Edges Higher After AstraZeneca Deal And Trial Focus
Insider Monkey
·
преди 1 ден
AstraZeneca’s Shares Have Fallen, but Is 14.6x Forward Earnings a Buying Opportunity?
Traders Union
·
преди 1 ден
AstraZeneca shares technical analysis: Upward price move confirms strong near-term momentum
The Twelfth Magpie
·
преди 2 дни
While the market panics about the FTSE 100, Citi just raised its AstraZeneca target to £186
Профил
AstraZeneca plc is a Swedish–British multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. Zeneca shareholders received 53.5% of the shares, while Astra shareholders received the remaining 46.5%. Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology, MedImmune, Spirogen and Definiens. It has its research and development concentrated in three strategic centres: Cambridge, England; Gothenburg, Sweden; and Gaithersburg, Maryland, US.
AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in Södertälje. Wikipedia
Всичко за AstraZeneca
Главен изпълнителен директорPascal Soriot
Служители96,1 хил.
Дата на основаване6.04.1999 г.
Централен офисКеймбридж, Кеймбриджшир, Великобритания
Бранш-
Уебсайтastrazeneca.com